Molecular Partners AG (MOLN)
Designs engineered proteins that target cancer cells for treatment in clinical trials.
$3.83-0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+8.5%
The outlook
MOLN trades near the lower end of its 52-week range, well below both its 50- and 200-day moving averages. Analysts are solidly bullish with a Strong Buy consensus, and their average price target sits roughly 186% above the current price. The overall outlook reflects this disconnect—cautious near-term technicals paired with notably optimistic analyst expectations.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range22% of the way from its 52-week low to high
Price targetAvg target +186% vs current price
Analyst price target
~12-month · 5 analysts$10.97average target+186.5% vs now
Now $3.83
Low $3.70High $16.73
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$143.7M
52-wk high
$5.36
52-wk low
$3.41
50-day avg
$3.94
200-day avg
$4.20
Trailing P/E
—